Non-fucosylated monoclonal human IgG1 antibody against human CD20

Anti-hCD20-hIgG1fut features the variable region of rituximab and the constant region of the human IgG1 isotype. Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes. Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity.

Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.

Anti-hCD20-hIgG1fut is a non-fucosylated antibody. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC) without any detectable change in complement-dependent cytotoxicity (CDC) or antigen binding capability [1, 2].

Anti-hCD20-hIgG1fut was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G.


Clonality: Non-fucosylated Monoclonal antibody
Specificity: Targets cells expressing human CD20
Isotype: Human IgG1
Application :
Anti-hCD20-hIgG1fut can be used with anti-hCD20-hIgG1 to compare the ADCC activity.

Quality control
- The absence of bacterial contamination (e.g. endotoxins and peptidoglycans) is controlled using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
- The recognition of human CD20 with this antibody is tested using flow cytometry.


100 µg purified anti-hCD20-hIgG1fut antibody, provided azide- free and lyophilized.

Product is shipped at room temperature. Store lyophilized antibody at -20°C.


1. Yamane-Ohnuki N. & Satoh M., 2009. Production of therapeutic antibodies with controlled fucosylation. corresponding MAbs. 1(3): 230–236.
2. Mizushima T., 2011. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells. 16(11): 1071–1080.


Recent articles using InvivoGen Anti-hCD20-hIgG1fut



Description Non-fucosylated Human CD20 (rituximab) antibody - Human IgG1
Cat. Codehcd20-mab13
Unit Size100 µg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "".